15 May 2002
Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
Witold PrejznerMed Sci Monit 2002; 8(5): BR193-197 :: ID: 420845
Abstract
BACKGROUND: Chronic myeloid leukemia is characterized by the presence ofthe Philadelphia chromosome. At the molecular level a fusion of part of the ABL and BCR genes is observed.The breakpoint locations in the BCR gene fall between exons b2a2 or b3a2 (5' and 3', respectively). Dependingon the BCR gene breakpoint two types of mRNA are created. Differences in the types of transcripts and/orthe breakpoint site may have an influence on the clinical course of the disease. This prompted the presentauthor to separate subtypes of chronic myeloid leukemia on the molecular level. MATERIAL/METHODS: 71patients diagnosed with chronic myeloid leukemia in the chronic phase were enrolled in the study. In61 patients the type of BCR/ABL transcript was determined, and in 27 patients BCR breakpoints were established.Possible correlations between the clinical course, prognostic indexes, survival and the type of transcriptand breakpoint were examined. RESULTS: No correlation between the clinical course, prognostic index,or survival was observed in patients with 5' and 3' breakpoints. The patients with b3a2 transcript experiencedlonger survival than the patients expressing b2a2 transcript. However, no significant differences wereobserved in the duration of the chronic phase between the two groups. CONCLUSIONS: The type of BCR genebreakpoint seems to have no prognostic value in patients with chronic myeloid leukemia. The longer survivalof patients expressing the b3a2 transcript may be caused by the less aggressive course of the acceleratedor blastic phase.
Keywords: Adolescent, DNA Damage, Fusion Proteins, bcr-abl, Genes, abl, Leukemia, Myeloid, Chronic, Mutation, RNA, Messenger, Reverse Transcriptase Polymerase Chain Reaction, Time Factors
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952